Aardvark Therapeutics (AARD) Assets Average (2025 - 2026)
Aardvark Therapeutics (AARD) posted Assets Average of $107.9 million for Q1 2026, down 13.83% sequentially from $125.2 million in Q4 2025, and down 8.0% YoY from $117.3 million in Q1 2025.
Aardvark Therapeutics (AARD) Assets Average (2025 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Assets Average for 2 years, with the latest figure at $107.9 million in Q1 2026.
- Quarterly Assets Average fell 8.0% year-over-year to $107.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107.9 million (down 8.0% YoY) and the FY2025 annual result came in at $97.3 million, changed N/A from the prior year.
- Assets Average declined to $107.9 million in Q1 2026 per AARD's latest filing, from $125.2 million in the prior quarter.
- Over five years, Assets Average peaked at $152.2 million in Q2 2025 and troughed at $107.9 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.82 Bn |
| 10 | Aardvark Therapeutics | 149.43 Mn | 75.51 Mn | - | 90.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90.03 Mn |
| Mar 31, 2026 | 107.89 Mn |
| Dec 31, 2025 | 125.21 Mn |
| Sep 30, 2025 | 140.35 Mn |
| Jun 30, 2025 | 152.25 Mn |
| Mar 31, 2025 | 117.27 Mn |